ClinicalTrials.gg
CompletedNCT04328506Updated Nov 26, 2021

Bioequivalency Study of CM082 Tablet in Healthy Volunteers

A Phase 1 interventional study of CM082 tablet (test product) and CM082 tablet (reference product) in Advanced Malignant Solid Tumors, sponsored by AnewPharma. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-26.

Sponsored by AnewPharma (part of Betta Pharmaceuticals Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers.

Read the detailed description

The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers under fasted state or after meal. In addition, the safety of single dose administration of CM082 tablet in Chinese healthy volunteers will also be evaluated.

02

Conditions studied

  • Advanced Malignant Solid Tumors
03

In context

Lead sponsor

AnewPharma is the lead sponsor of 14 studies on the registry; none are open to participants now.

First submitted after AnewPharma became part of Betta Pharmaceuticals Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male body weight≥50.0kg or female body weight≥45.0kg; between 19.0-26.0 kg/m2(inclusive)
  • Generally in good health, with no history of chronic disease or sever disease
  • No (clinical significant) abnormal findings in clinical laboratory tests and physical examinations
  • No plan for pregnancy in coming 6 months, and must practice effective ; No plan for sperm or egg donation
  • Written

Exclusion criteria

Exclusion Criteria:

  • History of food or drug allergies
  • Clinical significant disease or disorders
  • Received surgery in 3 months before screening, or have plan for surgery during the study
  • Participated in other clinical trials within 3 months before screening
  • Intolerant of venipuncture, history of fainting needle and blood
  • Lactose intolerant
  • Drug abusing in 3 months
  • Donated ≥200 mL of blood within 3 months before screening
  • Pregnant or under lactation period (female subjects)
  • Received any prescription drug, over-the-counter drug, prescription drug and Chinese herbal drug in 2 weeks, with the exception of vitamins and acetaminophen
  • Received any vaccine in 4 weeks
  • Excessively smoking, alcohol or coffin-containing beverage drinking in 3 months
  • Other circumstances that is deemed not appropriate for the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    T-R cohort under fasted state

    Subjects will be administered with one single dose of CM082 tablet (test product) under fasted state, after a wash period of 5 days, the subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state.

    Drug: CM082 tablet (test product) · Drug: CM082 tablet (reference product)

  • Experimental
    R-T cohort under fasted state

    Subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (test product) under fasted state.

    Drug: CM082 tablet (test product) · Drug: CM082 tablet (reference product)

  • Experimental
    T-R cohort after meal

    Subjects will be administered with one single dose of CM082 tablet (test product) after meal, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (reference product) after meal.

    Drug: CM082 tablet (test product) · Drug: CM082 tablet (reference product)

  • Experimental
    R-T cohort after meal

    Subjects will be administered with one single dose of CM082 tablet (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of CM082 tablet (test product) after meal

    Drug: CM082 tablet (test product) · Drug: CM082 tablet (reference product)

Interventions

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration(Cmax) of CM082 (test product or reference product) under fasted state or after meal

    The Cmax ofCM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose

    Time frame: pre-dose(30minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,16,24,36,48,72 hour]

  2. Area under the plasma concentration versus time curve(AUC) of CM082 (test product or reference product) under fasted state or after meal

    The AUC of CM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose

    Time frame: pre-dose(30minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,16,24,36,48,72 hour]

  3. Time of maximum concentration (Tmax) of CM082 (test product or reference product) under fasted state or after meal

    The Tmax of CM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose

    Time frame: pre-dose(30minute),30min,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,16,24,36,48,72 hour]

Secondary outcomes

  1. Percentage of adverse events

    Percentage of adverse events as assessed by CTCAE v4.03

    Time frame: From the first occurrence of adverse events after administration to the cessation of adverse events, assessed up to 2 months

07

Study locations

1 site
  • The 1st Phase Clinical Research Center of the Second Affiliated Hospital of Zhejiang University Medical College
    Hangzhou, Zhejiang 311009, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jul 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Mar 31, 2020
StartActual
Jun 1, 2020
Primary completionActual
Jul 27, 2020
CompletionActual
Jul 27, 2020
Last update
Nov 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04328506
Lead sponsor
AnewPharma
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Jun 1, 2020
Primary completion
Jul 27, 2020
Completion
Jul 27, 2020
Last update
Nov 26, 2021

Study contacts

zourong ruan
study chair · the Second Affiliated Hospital of Zhejiang University Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorolanib

Start the discussion